Adverse events associated with Azithromycin and clarithromycin in adults aged ≥65: a disproportionality analysis of the FDA adverse event reporting system (FAERS) database

Azithromycin and clarithromycin are commonly used to treat community-acquired pneumonia in adults aged ≥ 65, such as mycoplasma pneumonia. This study aims to evaluate adverse events (AEs) associated with azithromycin and clarithromycin in this age group by analyzing the FDA Adverse Event Reporting System (FAERS), providing insights for clinical use and management of AEs in this population.